Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell...

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Immunoglobulin idiotypic structures were the first tumor-specific determinants identified in malignant B cells.
• Clinical vaccination trials have shown induction of tumor-specific immunity, but the role of immunoglobulin-specific CD8+ cytotoxic T lymphocytes (CTLs) in tumor rejection is unclear.

Purpose of the Study:

• To identify human immunoglobulin-derived peptides that can induce CTL responses.
• To investigate the potential of targeting shared immunoglobulin peptides for improved B-cell malignancy vaccination strategies.

Main Methods:

• Combined bioinformatics analysis with a T cell-expansion system to identify immunogenic peptides.
• Tested the ability of human-leukocyte-antigen-matched and autologous CTLs specific for these peptides to kill primary malignant B cells.

Main Results:

• Identified immunogenic peptides derived from framework regions of immunoglobulin variable regions, which were shared among patients.
• Demonstrated that human-leukocyte-antigen-matched and autologous CTLs specific for these shared peptides effectively killed primary malignant B cells.
• Confirmed that malignant B cells can process and present these immunoglobulin-derived peptides.

Conclusions:

• Shared immunoglobulin-derived peptides can elicit specific cytotoxic T-lymphocyte responses against malignant B cells.
• Targeting these shared peptides represents a promising strategy to enhance current vaccination approaches for B-cell malignancies.